ArticleTherapeutic advances in musculoskeletal disease2026
Evaluation of hematological parameters as biomarkers of disease activity in drug-naïve patients with rheumatoid arthritis: a retrospective analysis.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory processes play a central role in rheumatoid arthritis (RA), involving complex interactions among cytokines and blood cell components. Current clinical tools, including the Disease Activity Score (DAS28), and biomarkers such as erythrocyte sedimentation rate and C-reactive protein (CRP), have limitations in monitoring disease activity. Objectives: This study aimed to assess the utility of routine hematological parameters as potential biomarkers for diagnosing RA and evaluating disease activity in drug-naïve patients. Methods: In this single-center retrospective study, 486 RA patients and 301 age- and sex-matched healthy controls were analyzed. Drug-naïve RA patients (not treated with disease-modifying antirheumatic drugs or glucocorticoids) were selected according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Hematological parameters (white blood cell count and differential, hemoglobin (HGB), platelet count (PLT), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), red cell distribution width (RDW), and mean platelet volume (MPV)) were obtained and calculated from complete blood counts. Disease activity was assessed using the 28-joint DAS28 with CRP. Diagnostic accuracy and association with disease activity were evaluated using receiver operating characteristic (ROC) analysis, correlation tests, and logistic regression. Results: Compared with controls, RA patients exhibited distinct hematological profiles, with significantly higher NLR, PLR, and RDW, and lower MPV (all Conclusion: This study suggests that hematological indices, particularly NLR, PLR, and MPV, hold potential as supplementary biomarkers in RA, but not standalone diagnostic tools. MPV emerged as an independent marker associated with higher disease activity, yet its clinical significance requires further validation. These readily available parameters may be integrated as complementary components of a broader diagnostic and monitoring strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.